Robert Half Names Paul Flaharty Executive Director for Marketing and Creative Practice Group

PR Newswire

MENLO PARK, Calif., Jan. 19, 2022 /PRNewswire/ — Paul Flaharty, a 16-year veteran of talent solutions and business consulting firm Robert Half, has been promoted to executive director, overseeing the company’s marketing and creative practice group. In this role, he will lead operational strategy for the placement of creative, digital, marketing, advertising and public relations talent to companies across the globe.

Since joining Robert Half, Flaharty has held several leadership roles with the company, most recently serving as district president for the technology, marketing and creative practice groups in the western United States. During his tenure, Flaharty has achieved companywide recognition for outstanding leadership and production, and for his contributions to business transformation.

“In this world of remote work, companies can now access the creative talent they need from anywhere, allowing them to stay competitive and innovative in their approach to customer engagement,” said Paul F. Gentzkow, president and CEO of talent solutions at Robert Half. “I am thrilled to have Paul in this role, and I know that through his leadership and industry expertise, we will take our business in this space to new heights.”

About Robert Half

Robert Half (NYSE: RHI) is the world’s first and largest specialized talent solutions and business consulting firm that connects opportunities at great companies with highly skilled job seekers. Robert Half offers contract, temporary and permanent placement solutions and is the parent company of Protiviti®, a global consulting firm. Visit roberthalf.com and download our award-winning mobile app.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/robert-half-names-paul-flaharty-executive-director-for-marketing-and-creative-practice-group-301463639.html

SOURCE Robert Half

Industry Continues to Rank Procore Project Management Software #1 in 2021 JBKnowledge Construction Technology Report

Industry Continues to Rank Procore Project Management Software #1 in 2021 JBKnowledge Construction Technology Report

CARPINTERIA, Calif.–(BUSINESS WIRE)–Procore Technologies, Inc. (NYSE: PCOR), a leading global provider of construction management software, today announced that it has been ranked as the number 1 construction project management software by the 2021 JBKnowledge Construction Technology Report.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005464/en/

Procore has been ranked as the #1 construction project management software by the JBKnowledge Construction Technology Report. (Graphic: Business Wire)

Procore has been ranked as the #1 construction project management software by the JBKnowledge Construction Technology Report. (Graphic: Business Wire)

Since 2012, JBKnowledge has surveyed thousands of construction professionals annually to provide a better understanding of the latest industry tech trends and insights. For the fifth consecutive year, Procore has maintained its status as the industry’s top choice for project management software.

“The 2021 Construction Technology Report recognizes the positive impact of Procore’s solutions on the construction industry,” said James Benham, CEO of JBKnowledge. “The report highlights the growing adoption and evolution of technology within the built environment.”

Respondents also named Procore as the number 1 mobile app of choice for daily reporting, photo/video capture, managing plans, safety management, and time management.

“For 20 years Procore has been dedicated to providing the best project management tools to the construction industry,” said Tooey Courtemanche, Procore founder and CEO. “Receiving this recognition from the construction industry itself is an honor and a testament to our commitment to, and partnership with, the industry.”

Report Insights

The Procore Platform helps construction professionals manage projects with complete visibility by housing every app, document, and stakeholder under one single source of truth.

According to the report, the top five reasons companies use mobile devices in the field are: daily reporting, photo/video capture, time management, safety management, and plan management. Procore also ranked as the #1 solution for construction across all five of these categories.

Procore’s cloud-based platform brings the most important mobile solutions for the job into a single integrated solution. Over 20% of total survey respondents reported using three mobile construction apps every day.

The Procore Platform currently offers 300+ integrations via the Procore App Marketplace, including Sage and Viewpoint, which ranked as the #1 and #2 Top Accounting/ERP Software.

“We have Procore and the Sage 100 Contractor integration, and the two are in constant sync,” said Heather Mertz, CFO, Mertz Group. “That’s huge, because we’re able to work together seamlessly as a team.”

Procore enables all construction stakeholders to connect and stay aligned across locations and devices. The Procore platform helps customers increase productivity and efficiency, reduce rework and costly delays, improve safety and compliance, and have more financial transparency and accountability.

Learn more about how Procore is helping to support the construction industry and download the 2021 Construction Technology Report from JBKnowledge.

About Procore

Procore is a leading provider of construction management software. Over 1 million projects and more than $1 trillion USD in construction volume have run on Procore’s platform. Our platform connects every project stakeholder to solutions we’ve built specifically for the construction industry—for the owner, the general contractor, and the specialty contractor. Procore’s App Marketplace has a multitude of partner solutions that integrate seamlessly with our platform, giving construction professionals the freedom to connect with what works best for them. Headquartered in Carpinteria, California, Procore has offices in the United States, Canada, and around the globe. Learn more at Procore.com.

PROCORE-IR

Media Contact

Andee Brooker

[email protected]

Investor Contact

Matthew Puljiz

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Mobile/Wireless Technology Construction & Property Accounting Professional Services Software Architecture Data Management Residential Building & Real Estate

MEDIA:

Logo
Logo
Photo
Photo
Procore has been ranked as the #1 construction project management software by the JBKnowledge Construction Technology Report. (Graphic: Business Wire)
Photo
Photo
Survey respondents rank Procore as the #1 construction project management software. (Graphic: Business Wire)
Photo
Photo
Procore ranked as the #1 solution for construction across the top 5 reasons companies use mobile devices in the field. (Graphic: Business Wire)
Photo
Photo
Over 20% of total survey respondents reported using three mobile construction apps every day. (Graphic: Business Wire)

Robert Half Names Brandi Britton Executive Director for Contract Finance and Accounting Practice Group

PR Newswire

MENLO PARK, Calif., Jan. 19, 2022 /PRNewswire/ — Brandi Britton, a 22-year veteran of talent solutions and business consulting firm Robert Half, has been promoted to executive director, overseeing the company’s contract finance and accounting practice group. In this role, she will lead global operational strategy for the placement of highly skilled finance and accounting professionals on a contract basis, for short- and long-term assignments.

Since joining Robert Half, Britton has held several leadership positions with the company, most recently serving as district president for professional talent solutions in Southern California. During her tenure, Britton has achieved companywide recognition for outstanding leadership and production.

“The current employment market demands flexibility, and hiring contract talent is one strategy companies have adopted to stay nimble and keep critical projects moving,” said Paul F. Gentzkow, president and CEO of talent solutions at Robert Half. “As Brandi is one of our most tenured and celebrated company leaders, I am confident in her ability to implement innovative strategies to grow this critical business unit, and I look forward to her continued success.”

About Robert Half
Robert Half (NYSE: RHI) is the world’s first and largest specialized talent solutions and business consulting firm that connects opportunities at great companies with highly skilled job seekers. Robert Half offers contract, temporary and permanent placement solutions and is the parent company of Protiviti®, a global consulting firm. Visit roberthalf.com and download our award-winning mobile app.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/robert-half-names-brandi-britton-executive-director-for-contract-finance-and-accounting-practice-group-301463634.html

SOURCE Robert Half

TracyLocke and the LEGO Group Launch the “Store of the Future”

First-of-its-kind immersive digital and physical shopper experiences give a glimpse into the future of branded retail

PR Newswire

DALLAS, Jan. 19, 2022 /PRNewswire/ — TracyLocke, leading commerce and communications agency, is partnering with the LEGO Group to activate the launch of its “Store of the Future” – a global retail concept rooted in a shopper journey of creativity and imagination.

With expertise in compelling commerce through creativity and brand experience, TracyLocke approached the global campaign with a hyper-local strategy, creating campaigns that appeal broadly to tourists while speaking endearingly to locals in both New York City and Barcelona.

“Our flagship store should always offer the most engaging and innovative experience for our visitors, inspiring creativity, building brand love and encouraging hands-on play,” said Stephane Knapp, Sr. Director of Regional Retail Marketing at the LEGO Group. “Since our first day working together, the TracyLocke team fit right in with creative ideas that bring the LEGO brand values to life through authentic, unique experiences in each market.”

TracyLocke’s involvement began with the new LEGO flagship store in New York City, focused on digital and social with a theme of “If you can build it here, you can build it anywhere.” The partnership peaked with the launch of the Barcelona store with a full omni-channel marketing campaign, complete with a never-been-done-before experiential event to drive earned attention, engagement and visits.

The Barcelona flagship store design was inspired by architect Antoni Gaudí, known for inventing the mosaic art style Trencadis – a process of breaking a porcelain object into smaller pieces to create mosaic artwork more effectively. TracyLocke took a page from Gaudí’s style and celebrated the Barcelona store opening by dropping a 265-pound, nine-foot diameter Trencadis plate made with more than 250,000 LEGO bricks. To bring the experience in store, guests could pick up the loose LEGO bricks and take them inside to complete their own mosaic tile creations in true Gaudí fashion.

“The Barcelona store concept cultivated from a connection between LEGO brand values and the cultural heritage of the city,” said Tina Manikas, TracyLocke President. “Our joint focus on creativity and the future of retail makes for a strong continued partnership. We look forward to additional flagship store launches and continued growth with the LEGO Group.”

TracyLocke began work with the LEGO Group in March 2021 and will continue supporting “Store of the Future” concepts localized to additional markets to pilot the future of branded retail. The agency is currently working on the next store opening in Chengdu, China, scheduled for February 2022.

About TracyLocke: 
TracyLocke is an award-winning global agency that leverages insightful creativity and design thinking to drive commerce. With offices in North America and around the world, its employees are a blend of talented individuals with unique strengths, experiences and backgrounds. TracyLocke is part of the Omnicom Commerce Group and partners with clients such as PepsiCo, SC Johnson, Diageo, Pizza Hut, Godiva, Samsung, and the Dollar General Literacy Foundation. For more information about TracyLocke, visit www.tracylocke.com

About Omnicom Commerce Group: 
Omnicom Commerce Group (OCG) is a global community of four award-winning commerce agencies, working with brands and retailers to offer best in class consultancy, creativity and capability focused on driving increased conversion and transaction. OCG’s priority is to address the need for innovative multi-channel commerce expertise in the rapidly evolving world of retail and shopping. OCG encompasses 2,500 people across 19 markets. For more information, visit www.omnicomcommercegroup.com. OCG is part Omnicom Group Inc. (NYSE: OMC), a leading global marketing and corporate communications company. 

 

Cision View original content:https://www.prnewswire.com/news-releases/tracylocke-and-the-lego-group-launch-the-store-of-the-future-301463623.html

SOURCE TracyLocke

Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients

New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million

CAMBRIDGE, Mass., Jan. 19, 2022 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, are expanding their existing partnership to develop tebipenem as a treatment for complicated urinary tract infections (cUTI), including pyelonephritis, in pediatric patients.

BARDA added, and exercised, a new option on the contract originally awarded to Spero in 2018. The new option increases the total amount of committed funding by $12.9M to $46.9M, increasing the total potential contract value to $59.7M. As previously announced, the Defense Threat Reduction Agency (DTRA) is providing up to approximately $10.0M, in addition to the total potential award from BARDA, to cover the cost of the nonclinical biodefense aspects of the collaboration program for tebipenem HBr. The additional $12.9M option is expected to provide support for a clinical trial and related activities for orally administered tebipenem pivoxil’s use in treating pediatric patients with cUTI, including AP.

“We are pleased to expand our relationship with BARDA and look forward to continuing our productive collaboration,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “This new option award not only provides further external validation for tebipenem HBr and its robust clinical dataset, but also allows us to pursue development of tebipenem for use in pediatric patients with cUTI. We would like to thank BARDA for their continued collaboration, as we work to address oral alternatives to treat multi-drug resistant bacterial infections, providing therapeutic options to those adults and children with unmet needs.”

Spero currently has a New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment in adult patients with cUTI, including pyelonephritis, caused by susceptible microorganisms, under review by the United States Food and Drug Administration (FDA).

Tebipenem HBr Research Support

This project has been funded in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.

About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in cUTI, including pyelonephritis. On January 3, 2022, Spero announced that FDA has accepted its NDA for tebipenem HBr tablets.

Tebipenem HBr is an investigational drug in the United States and is currently not approved for the treatment of complicated urinary tract infection, including pyelonephritis.

Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Forward Looking Statements

This press release may contain forward-looking statements. These statements include, but are not limited to, potential approval of tebipenem HBr by the FDA; potential funding by the DTRA; potential payments under Spero’s agreement with BARDA; future clinical trials for pediatric use of tebipenem HBr; future use of tebipenem HBr for pediatric patients; the timing of launch of tebipenem HBr; the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; the effectiveness of tebipenem HBr and its potential impact on healthcare resource utilizations; the anticipated shift from IV to oral administration; the sufficiency of Spero’s cash resources and Spero’s anticipated expenses; and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards . In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the COVID-19 pandemic; the timing and content of advice given and decisions made by regulators, including the FDA; Spero’s need for additional funding; the lengthy, expensive, and uncertain process of clinical drug development; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to develop and commercialize Spero’s product candidates, if approved; the potential impact of the COVID-19 pandemic; Spero’s ability to retain key personnel and to manage its growth; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.

Investor Relations Contact: 
Ted Jenkins
Vice President, Investor Relations and Specialty Finance
[email protected]
(617) 798-4039

Media Contact:

Jacqueline Pomfret Kirby
Vice President, Corporate Affairs
[email protected]
(617) 798-4074



Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

Live video webcast presentation on Tuesday, January 25th at 3:00 PM ET

ISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will participate in the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 3:00 PM ET.

As part of the virtual event, Outlook Therapeutics will provide a corporate presentation, followed by a moderated interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.

A live video webcast of the presentation will be available on the Events page of the Investors section of Outlook Therapeutics’ website (outlooktherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:

Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
[email protected]

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247 
[email protected]



Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium

Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium

New Guardant Reveal™ data from interim analysis of COSMOS-CRC-01 demonstrates high performance for recurrence detection in early-stage colorectal cancer

REDWOOD CITY, Calif.–(BUSINESS WIRE)–
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present data highlighting the clinical utility of its liquid biopsy tests in the treatment and management of early- to late-stage gastrointestinal cancers, including colorectal cancer, at the 2022 ASCO Gastrointestinal Cancers Symposium being held January 20-22, 2022.

An interim analysis from COSMOS-CRC-01, a large, prospective, observational study, shows that the Guardant Reveal™ liquid biopsy test, when performed after curative intent surgery for stage II-III colorectal cancer, can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time of greater than six months. The test integrates genomic and epigenomic signatures to detect disease without the need for tumor tissue. (Abstract 168)

Additionally, clinical utility data will demonstrate that the Guardant360® liquid biopsy test detects microsatellite instability-high (MSI-H) status in patients with advanced gastrointestinal cancers at a similar frequency to tissue-based testing1,2. MSI-H is an important biomarker used to predict response to immunotherapy. Also, real-world clinical outcomes data from the GuardantINFORM™ platform showed that colorectal cancer patients who received immune checkpoint blockade therapy after MSI-H status identification with Guardant360 achieved responses in line with published data in previously treated MSI-H advanced gastrointestinal cancers1,2. (Abstract 56)

“These studies further demonstrate the significant clinical value that our blood tests offer in detecting and monitoring cancer, which can help physicians make informed treatment decisions in patients with early- or late-stage gastrointestinal cancer without the need for an invasive tissue biopsy,” said Helmy Eltoukhy, Guardant Health co-CEO. “Tissue biopsies can be difficult to obtain, time-consuming, and lead to complications, all of which can delay a patient’s treatment. Our blood-based tests can overcome these barriers and provide fast and actionable information to help guide treatment decisions across the continuum of care.”

Full List of Guardant Health Presentations:

  • Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA (ctDNA) on recurrence in resected colorectal cancer: Initial report of a prospective ctDNA monitoring study COSMOS-CRC-01 (Abstract 168)
  • Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI) (Abstract 56)
  • Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) (Abstract TPS233)
  • Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial (Abstract 193)
  • Minimal residual disease assessment in colorectal cancer (MiRDA-C) (Abstract TPS236)
  • Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling (Abstract 152)
  • Evaluation of baseline BRAF V600E mutation in circulating tumor DNA and efficacy response from the BEACON study (Abstract 162)
  • The role of serial analysis of hepatocellular carcinoma via circulating tumor DNA in identification of new actionable alterations (Abstract 478)
  • Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer (Abstract 594)
  • Does detection of microsatellite instability-high (MSI-H) by plasma-based testing predict tumor response immunotherapy (IO) in patients with pancreatic cancer? (Abstract 607)

The full abstracts can be found at the official ASCO Gastrointestinal Cancers Symposium website here.

About the Guardant360 Liquid Biopsy Test

The Guardant360 liquid biopsy test is part of the market-leading Guardant360 portfolio that offers oncologists end-to-end testing solutions from treatment selection to treatment response monitoring. Since it was first introduced, the Guardant360 blood test has become widely accepted for blood-based comprehensive genomic profiling (CGP) with more than 260 peer-reviewed publications including over 80 clinical outcomes studies. It has been trusted by more than 11,000 oncologists with more than 250,000 tests performed to date.

About GuardantINFORM

The GuardantINFORM clinical-genomic platform is intended to help accelerate research and development of the next generation of cancer therapeutics by offering biopharma partners an in-silico platform that combines de-identified longitudinal clinical information and genomic data collected from the Guardant360 liquid biopsy test. With data from more than 160,000 patients diagnosed with locally advanced and metastatic cancers, this robust dataset offers real-world insights into anti-cancer therapy use in the clinic, tumor evolution, and treatment resistance throughout each patient’s treatment journey for many advanced solid tumor cancers, including non-small cell lung, breast, colon, and prostate.

About Guardant Reveal

Guardant Reveal test the first blood-only test that detects residual and recurrent disease in patients with Stage II and III CRC in under two weeks without the need for a tissue biopsy. The test detects ctDNA in blood after surgery to identify patients with residual disease who may benefit most from adjunctive therapy, and to monitor for recurrence of CRC in previously diagnosed patients.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

References

  1. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342-1350.
  2. Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. Published online October 3, 2017.

 

Investor Contact:

Carrie Mendivil

[email protected]

+1 415-937-5405

Media Contact:

Michele Rest

[email protected]

+1 215-910-2138

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Health Oncology Medical Devices

MEDIA:

Logo
Logo

SES Announces Signing of “A-sample” Joint Development Agreement with Honda, the Largest Investor in the SES-Ivanhoe Capital PIPE Financing

SES Announces Signing of “A-sample” Joint Development Agreement with Honda, the Largest Investor in the SES-Ivanhoe Capital PIPE Financing

  • Honda joins General Motors and Hyundai Motor Company as the third major global car manufacturer to enter into an “A-sample” joint development agreement with SES.
  • Honda previously agreed to be the largest single investor in the $275 million PIPE financing in connection with the pending SES-Ivanhoe business combination.
  • Honda is joining industry leaders General Motors, Hyundai Motor Company, Geely Holding Group, SAIC Motor and Foxconn as the sixth major global car manufacturer to invest in the combined company.

BOSTON–(BUSINESS WIRE)–
SES Holdings Pte. Ltd. (SES), a global leader in the development and production of high-performance hybrid lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, announced today that it entered into a Joint Development Agreement with Honda Motor Co. Ltd. (Honda) to develop Li-Metal batteries as part of Honda’s next generation battery strategy. The partnership marks a key milestone on SES’ strategic roadmap to achieve commercial production of hybrid Li-Metal batteries for electric vehicles. Honda joins General Motors and Hyundai Motor Company as the third major global car manufacturer to enter into an “A-sample” joint development agreement with SES.

Honda previously agreed to invest in the combined company as part of the common stock private investment in public equity (“PIPE”) financing in connection with SES’ pending business combination with Ivanhoe Capital Acquisition Corp. (NYSE: IVAN) (“Ivanhoe”). Honda agreed to join industry leaders General Motors, Hyundai Motor Company, Geely Holding Group, SAIC Motor and Foxconn as the sixth major international car manufacturer to invest in the combined company. Immediately following the business combination, PIPE proceeds are expected to total $275 million and Honda will be the largest single PIPE investor owning approximately 2% of the outstanding shares of the combined company (assuming no redemptions by public shareholders of Ivanhoe).

Honda has been looking into several options toward the realization of high-capacity, safe and low-cost next-generation batteries. The joint development agreement, following Honda’s previous agreement to invest in the PIPE, is a testament to Honda’s long-term plan to leverage key technologies SES has developed to broaden options for next-generation batteries for Honda.

“We are thrilled to have Honda sign a joint development agreement following its agreement to invest in the PIPE, and look forward to building upon this important strategic partnership,” said Qichao Hu, SES Founder and Chief Executive Officer “Our innovative hybrid lithium-metal technology is a compelling solution for combining higher energy density with industry leading performance characteristics and high manufacturability. As we look beyond the expected close of the business combination, through the support of Honda and all of our strategic and financial investors, we are well positioned to execute our development and production plans to bring next generation battery technology to global EV manufacturers.”

“The battery is an essential component of EVs, and Honda has been concurrently looking into several options toward realization of high-capacity, safe and low-cost next-generation batteries,” says Shinji Aoyama, Managing Executive Officer in Charge of Electrification, Honda Motor Co., Ltd. “Recognizing the advanced technologies of SES, Honda signed a joint development agreement with SES with the aim of establishing a good relationship with SES and expeditiously generating substantial achievements through our joint research activities. Honda will continue to establish collaborative relationships with companies which have advanced technologies, as needed, to offer highly-competitive and attractive EVs to our customers.”

As previously disclosed, in July 2021, SES announced plans to list on the New York Stock Exchange (NYSE) through a business combination with Ivanhoe. Upon the closing of the transaction, the combined company will be named SES AI Corporation. The parties expect that the Class A common stock and warrants of the combined company will be listed on the NYSE under the ticker symbols “SES” and “SESW,” respectively. On January 10, 2022, SES announced that the U.S. Securities and Exchange Commission (the “SEC”) declared effective Ivanhoe’s registration statement on Form S-4 (File No. 333-258691) related to the proposed business combination of Ivanhoe and SES, and Ivanhoe has mailed a definitive proxy statement/prospectus to its shareholders and public warrant holders of record as of December 14, 2021 who are entitled to vote at its Extraordinary General Meeting of Shareholders and Special Meeting of Warrant Holders to be held on February 1, 2022 at 9:00 a.m. ET and 9:15 a.m. ET, respectively, to approve the proposed business combination, certain changes to Ivanhoe’s warrants and the other matters proposed to be voted on at such meetings.

About SES

SES is a global leader in development and production of high-performance Li-Metal rechargeable batteries for electric vehicles (EVs) and other applications. Founded in 2012, SES is an integrated Li-Metal battery manufacturer with strong capabilities in material, cell, module, AI-powered safety algorithms and recycling. Formerly known as SolidEnergy Systems, SES is headquartered in Boston and has operations in Singapore, Shanghai, and Seoul. To learn more about SES, please visit: ses.ai/investors/

About Ivanhoe Capital Acquisition Corp.

Ivanhoe Capital Acquisition Corp. (NYSE: IVAN) is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Ivanhoe was formed to seek a target in industries related to the paradigm shift away from fossil fuels towards the electrification of industry and society. To learn more about Ivanhoe, please visit: ivanhoecapitalacquisition.com

Forward-looking statements

All statements other than statements of historical facts contained in this press release are “forward-looking statements.” Forward-looking statements can generally be identified by the use of words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” “target” and other similar expressions that predict or indicate future events or events or trends that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the business combination and the related PIPE financing, the timing of the business combination, the Extraordinary General Meeting of Ivanhoe’s shareholders and the Special Meeting of Ivanhoe’s warrant holders, statements regarding the development and commercialization of SES’s products, including in connection with Joint Development Agreements, the amount of capital and other benefits to be provided by the business combination and the related PIPE financing, estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of SES’s and Ivanhoe’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of SES and Ivanhoe. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; the inability of the parties to successfully or timely consummate the business combination, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the business combination or that the approval of the shareholders of SES or Ivanhoe is not obtained; the failure to realize the anticipated benefits of the business combination; risks relating to the uncertainty of the projected financial information with respect to SES; risks related to the development and commercialization of SES’s battery technology and the timing and achievement of expected business milestones; the effects of competition on SES’s business; the risk that the business combination disrupts current plans and operations of Ivanhoe and SES as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and retain its management and key employees; risks relating SES’s history of no revenues and net losses; the risk that SES’s joint development agreements and other strategic alliances could be unsuccessful; risks relating to delays in the design, manufacture, regulatory approval and launch of SES’s battery cells; the risk that SES may not establish supply relationships for necessary components or pay components that are more expensive than anticipated; risks relating to competition and rapid change in the electric vehicle battery market; safety risks posed by certain components of SES’s batteries; risks relating to machinery used in the production of SES’s batteries; risks relating to the willingness of commercial vehicle and specialty vehicle operators and consumers to adopt electric vehicles; risks relating to SES’s intellectual property portfolio; the amount of redemption requests made by Ivanhoe’s public shareholders; the ability of Ivanhoe or the combined company to issue equity or equity-linked securities or obtain debt financing in connection with the business combination or in the future and those factors discussed in Ivanhoe’s Annual Report on Form 10-K filed with the SEC on March 31, 2021 and in Ivanhoe’s proxy statement/prospectus relating to the proposed business combination, filed with the SEC on January 7, 2022, including those under “Risk Factors” therein, and other documents of Ivanhoe filed, or to be filed, with the SEC relating to the business combination. If any of these risks materialize or Ivanhoe’s or SES’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither Ivanhoe nor SES presently know or that Ivanhoe and SES currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Ivanhoe’s and SES’s expectations, plans or forecasts of future events and views only as of the date of this press release. Ivanhoe and SES anticipate that subsequent events and developments will cause Ivanhoe’s and SES’s assessments to change. However, while Ivanhoe and SES may elect to update these forward-looking statements at some point in the future, Ivanhoe and SES specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Ivanhoe’s and SES’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Additional Information

This press release relates to the proposed business combination between Ivanhoe and SES. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Ivanhoe has filed a definitive proxy statement and a form of proxy card with the SEC in connection with the solicitation of proxies for the Extraordinary General Meeting of Ivanhoe’s shareholders (the “Definitive Proxy Statement”). The Definitive Proxy Statement has been sent to all Ivanhoe shareholders. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. Ivanhoe will also file other documents regarding the proposed business combination with the SEC. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF IVANHOE ARE URGED TO READ THE REGISTRATION STATEMENT, THE DEFINITIVE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION.

Investors and security holders are able to obtain free copies of the registration statement, the Definitive Proxy Statement and all other relevant documents filed or that will be filed with the SEC by Ivanhoe through the website maintained by the SEC at www.sec.gov. The documents filed by Ivanhoe with the SEC also may be obtained free of charge upon written request to Ivanhoe Capital Acquisition Corp., 1177 Avenue of the Americas, 5th Floor, New York, New York 10036.

Participants in the Solicitation

Ivanhoe, SES and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Ivanhoe’s shareholders in connection with the proposed Business Combination. You can find information about Ivanhoe’s directors and executive officers and their interest in Ivanhoe can be found in the Definitive Proxy Statement and Ivanhoe’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which was filed with the SEC on March 31, 2021. A list of the names of the directors, executive officers, other members of management and employees of Ivanhoe and SES, as well as information regarding their interests in the business combination, are contained in the Definitive Proxy Statement, and any changes will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Changes in Beneficial Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such potential participants in the solicitation process may also be included in other relevant documents when they are filed with the SEC. You may obtain free copies of these documents from the sources indicated above.

Media: Irene Lam [email protected]

Investors: [email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Automotive General Automotive Other Energy Automotive Manufacturing Manufacturing Other Automotive Alternative Energy Energy

MEDIA:

Walgreens Launches COVID-19 Index to Advance Rapid Detection of Omicron and Track Variant Activity by State

Walgreens Launches COVID-19 Index to Advance Rapid Detection of Omicron and Track Variant Activity by State

Data captured in the Walgreens COVID-19 Index tracks existing and emerging variants

DEERFIELD, Ill. & NASHVILLE, Tenn.–(BUSINESS WIRE)–
The Walgreens COVID-19 Index, a new interactive tracking tool from Walgreens, powered by testing data from Aegis Sciences Corporation, is among the first to uniquely identify the spread of current and emerging variants in near real-time.New data from the Walgreens COVID-19 Index shows more than 95% of all positive COVID-19 cases are presumed to be the Omicron variant. The data reinforces the importance of vaccinations and testing in helping to mitigate the spread of COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005357/en/

Data captured in the Walgreens COVID-19 Index can track the spread of the Omicron variant within 24 to 48 hours, more quickly than other methods. In addition to a national view, data can be reviewed by state. The Walgreens COVID-19 Index is based on proprietary data from PCR testing services administered by Walgreens and performed by its testing partner Aegis Sciences.

“Through Walgreens partnership with Aegis Sciences, we have the ability to provide this interactive tracking tool and inform the development of strategies and resources to help mitigate the spread of COVID-19,” said Dr. Kevin Ban, chief medical officer for Walgreens. “This provides a leading consumer-centric healthcare solution to support our communities and partners, building on our nationwide footprint and health offerings.”

Based on data analyzed as of Jan. 18, the following types of insights are available from the Walgreens COVID-19 Index:

  • Nationally, more than 95% of all positive cases are presumed to be the Omicron variant
  • Top states for COVID-19 positive rates are Alabama, Florida, Georgia, Mississippi, South Dakota, Nevada and Texas, which all have COVID-19 positivity rates over 45% of those tested
  • Top states for confirmed Delta case prevalence are Maine (43.5%), Kansas (36.5%), Iowa (29.2%), New Mexico (25.2%), Oklahoma (24.2%), Indiana (23.6%) and Utah (23.5%)

“Data regarding spread of variants is important to our understanding of viral transmission and, as new variants emerge, it will be critical to continue to track this information quickly to predict which communities are most at risk,” said Dr. Matthew Hardison, senior vice president of lab operations at Aegis Sciences Corporation. “We are pleased to partner with Walgreens to provide testing, collaborate on data analysis and provide timely insights that can help health departments curtail the COVID-19 pandemic.”

It remains critically important to get vaccinated or boosted against COVID-19, and is safe and convenient to get a COVID-19 vaccine or booster at one of Walgreens nearly 9,000 locations. For the best experience, patients are encouraged to make appointments for COVID-19 vaccinations and boosters through Walgreens.com/ScheduleVaccine or 1-800-WALGREENS.

Data will be updated frequently and provide a rolling snapshot of the previous 7 days’ data based on analysis of positive tests at more than 5,000 Walgreens testing locations. To view the Walgreens COVID-19 Index, maps and other online features, click here.

About the Walgreens COVID-19 Index

The Walgreens COVID-19 Index is the product of an innovative pharmacy-laboratory collaboration focused on helping communities, health professionals and the media stay informed about COVID-19 surveillance. The Walgreens COVID-19 Index is generated through the combination of Walgreens nationally representative PCR testing services with the associated PCR and Next-Generation Sequencing (NGS) laboratory test results generated by Aegis Sciences. The exhibits within the Index provide an overview of confirmed cases by state, presumed Omicron cases in near real-time, variant proportions over time and positivity rates by vaccination status. Walgreens and Aegis Sciences Corporation have collaborated to offer COVID-19 PCR testing at more than 5,000 Walgreens locations.

While generated from a large, nationally representative dataset, the data presented in the Walgreens COVID-19 Index is only reflective of real-time reverse transcriptase polymerase chain reaction (RT PCR) and NGS results from samples collected at specific Walgreens locations and tested by Aegis Sciences Corporation. It does not incorporate information from other testing modalities performed at or through Walgreens. Data regarding vaccination status is derived from information supplied in the test registration process by individuals that tested at Walgreens locations. The amount of data available varies by geographic location. All data presented in the Walgreens COVID-19 Index is aggregated and de-identified to protect individuals’ privacy.

About Walgreens

Walgreens (www.walgreens.com) is included in the United States segment of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. As America’s most loved pharmacy, health and beauty company, Walgreens purpose is to champion the health and well-being of every community in America. Operating nearly 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving approximately 9 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with fully integrated physical and digital platforms supported by the latest technology to deliver high-quality products and services in local communities nationwide.

About Aegis Sciences Corporation

Founded in 1990, Aegis Sciences Corporation is a laboratory sciences company based in Nashville, Tenn., that provides science-driven testing and consulting services to healthcare providers, pharmaceutical companies, professional and amateur sports organizations, leading college and university athletic programs, Fortune 500 corporations, and government agencies throughout the United States. Since launching COVID-19 testing in April 2020, Aegis has quickly increased testing capacity to meet the needs of communities across the United States. To date, Aegis has performed over 11 million COVID-19 tests and is the leading provider of SARS-CoV-2 genome sequencing results in the United States. For more information, please visit http://www.aegislabs.com/.

Rebekah Pajak

Walgreens Media Relations

[email protected]

Stephanie Protz

Aegis Sciences Corporation

[email protected]

KEYWORDS: Illinois Tennessee United States North America

INDUSTRY KEYWORDS: Research Medical Supplies Infectious Diseases Specialty Convenience Store Home Goods Pharmaceutical Health Retail Science

MEDIA:

Logo
Logo
Logo
Logo

Comerica Reports Fourth Quarter 2021 Earnings Results

PR Newswire

DALLAS, Jan. 19, 2022 /PRNewswire/ — Comerica Incorporated (NYSE: CMA) has reported its fourth quarter 2021 financial results. The results are available on the Investor Relations section of Comerica’s website here. In addition, the financial results and earnings presentation will be furnished on a Form 8-K filing that will be available on the Securities and Exchange Commission website at www.sec.gov.

As previously announced, Comerica will host a conference call to review the fourth quarter 2021 financial results. Interested parties may access the call and supplemental materials through the following details:


DATE:        

Wednesday, Jan. 19, 2022


TIME:                                              

9 a.m. CT / 10 a.m. ET           


PARTICIPANT DIAL-IN:    

(800) 309-2262 or (706) 679-5261

(Event ID No. 4719659)


WEBCAST / PRESENTATION:

The live audio webcast, earnings release and earnings presentation will be available on the Investor Relations Presentations and Events page on www.comerica.com.           


REPLAY INFORMATION:

A replay (accessible for one year) of the call is expected to be available approximately one hour after the live webcast on the Investor Relations Presentations and Events page on www.comerica.com.

Comerica Incorporated (NYSE: CMA) is a financial services company headquartered in Dallas, Texas, and strategically aligned by three business segments: The Commercial Bank, The Retail Bank, and Wealth Management. Comerica focuses on relationships, and helping people and businesses be successful. In addition to Texas, Comerica Bank locations can be found in Arizona, California, Florida and Michigan, with select businesses operating in several other states, as well as in Canada and Mexico.

         

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/comerica-reports-fourth-quarter-2021-earnings-results-301463840.html

SOURCE Comerica Incorporated